Biology of Reproduction, Vol 46, 898-904, Copyright © 1992 by Society for the Study of Reproduction

ARTICLES

Regulation of pulsatile gonadotropin secretion by estrogen, inhibin, and follistatin (activin-binding protein) in ovariectomized rats

LV Depaolo, M Shimonaka and N Ling
Department of Molecular Endocrinology, Whittier Institute for Diabetes and Endocrinology, La Jolla, California 92037.

The following study was conducted to examine the effects of estrogen and polypeptides, given either alone or in combination, on pulsatile gonadotropin secretion. One week after ovariectomy, rats received s.c. injections of oil or various doses (0.5, 5, 20 micrograms) of estradiol benzoate (EB) followed 1 day later by i.v. administration of 60 micrograms purified porcine follistatin, 10 micrograms recombinant inhibin, or the appropriate vehicle. Four hours after injection of the nonsteroids, blood was collected at 10-min intervals for 2 h, and the effects on pulsatile hormone release were assessed. Administration of EB alone dose-dependently suppressed mean and trough (lowest point between two pulses) FSH levels and all parameters of pulsatile LH release. Both follistatin and inhibin at the doses employed suppressed mean FSH levels to an equivalent extent (40%). Follistatin, but not inhibin, suppressed FSH pulse amplitude, while neither polypeptide alone influenced FSH pulse frequency or any parameter of pulsatile LH release. The effects of follistatin and EB on mean FSH levels were additive at all EB doses, whereas the effects of inhibin and EB were additive only at the middle EB dose. Follistatin in combination with the lowest EB dose significantly suppressed mean LH levels. These studies are the first to demonstrate that combined treatment with estrogen and the nonsteroids follistatin and inhibin is more efficacious in suppressing FSH release than treatment with either agent alone, thereby indicating that both steroids and nonsteroids are probably important in the physiological regulation of FSH secretion in rats. The additive effects of these compounds on FSH secretion could form the basis for exploring novel contraceptive interventions.

This article has been cited by other articles:

				V. Padmanabhan, D. Battaglia, M. B. Brown, F. J. Karsch, J. S. Lee, W. Pan, D. J. Phillips, and J. Van Cleeff Neuroendocrine Control of Follicle-Stimulating Hormone (FSH) Secretion: II. Is Follistatin-Induced Suppression of FSH Secretion Mediated via Changes in Activin Availability and Does It Involve Changes in Gonadotropin-Releasing Hormone Secretion? Biol Reprod, May 1, 2002; 66(5): 1395 - 1402. [Abstract] [Full Text]

				A. M. O. Leal, K. Takabe, L. Wang, C. J. Donaldson, L. A. MacConell, L. M. Bilezikjian, I. M. Verma, and W. Vale Effect of Adenovirus-Mediated Overexpression of Follistatin and Extracellular Domain of Activin Receptor Type II on Gonadotropin Secretion in Vitro and in Vivo Endocrinology, March 1, 2002; 143(3): 964 - 969. [Abstract] [Full Text] [PDF]

				F. Shi, M. Ozawa, H. Komura, P. Yang, A. L. Trewin, R. J. Hutz, G. Watanabe, and K. Taya Secretion of Ovarian Inhibin and Its Physiologic Roles in the Regulation of Follicle-Stimulating Hormone Secretion during the Estrous Cycle of the Female Guinea Pig Biol Reprod, January 1, 1999; 60(1): 78 - 84. [Abstract] [Full Text]